PUBLISHER: Knowledge Sourcing Intelligence | PRODUCT CODE: 1496025
PUBLISHER: Knowledge Sourcing Intelligence | PRODUCT CODE: 1496025
The global hypodermic needle market is expected to grow at a compound annual growth rate of 6.42% over the forecast period to reach a market size of US$4,690.217 million in 2029, from US$3,034.881 million in 2022.
A hypodermic needle is a medical instrument utilized for infusing substances or extricating liquids from the body, ordinarily through subcutaneous, intramuscular, or intravenous courses. It comprises a hollow, round, and empty tube with a sharp tip and plunger, permitting for exact organization of drugs, immunizations, or withdrawal of blood or other liquids.
The worldwide hypodermic needle advertise includes the manufacturing, distribution, and selling of hypodermic needles utilized within the healthcare industry. Key viewpoints of the market include safety needles, non-safety needles, applications, end-users, geographical nearness, administrative environment, unused improvements, industry key players, and open well-being activities. Safety needles focus on aspects like healthcare employee safety, lessening the hazard of needlestick wounds.
Non-safety needles are conventional needles without extra security components. The worldwide hypodermic needle market is energetic and affected by components such as innovative headways, healthcare approaches, and the predominance of maladies that require the utilize of hypodermic needles in restorative medical intercessions.
The market is predicted to experience a boost in the years ahead due to the increase in the prevalence rate of diabetes around the world. According to the information provided by the International Diabetes Federation, around 537 million adult individuals have been living with diabetes for years, between the ages of 20 and 79 category in the year 2021. Further, it has also been estimated that the global population living with diabetes is expected to grow to 643 million by 2030 and around 783 million by 2045.
Increasing global expenditure on diabetes has been expected to surge the adoption of advanced drug delivery solutions. Various companies and corporations have been offering advanced and novel solutions for diabetic patients, such as the easy delivery of drugs by needles in a patient's body.
Several firms and corporations have been making a considerable impact in the market in the past few years. The increasing expenditure on research and development was expected to surge in the next few years as corporations tend to increase their competitive advantage and overall market share globally. Iscon Surgicals Ltd., one of the key players in the market, has been providing and selling disposable hypodermic needles to its customers.
The company stated that its needle had been produced through high and advanced precision grinding, siliconization, and ultrasonic cleaning. The company's products are ISO Certified. Other corporations have been offering advanced hypodermic needles for their customers.
For instance, NIPRO, one of the largest needle manufacturers, produces around 11 billion units annually. The company stated that its products are not manufactured as PVC or latex. It also offers hypodermic needles in different lengths and sizes. These developments and trends are expected to play a significant role in the market during the forecast period.
Hypodermic needle utilization is anticipated to surge within the projected period due to the expanding rate of asthma, around the world. According to the information given by the World Wellbeing Organisation (WHO), asthma is additionally included in the WHO Worldwide Action Plan for the Prevention and Control of Noncommunicable Diseases (NCDs) and the United Nations 2030 Plan for Sustainable Development.
The WHO has also been undertaking a few measures to upgrade the drug conveyance segment in lower and middle-income nations. With expanding industrialization, there has been a concern around high contamination, which has been one of the major components of the expanding prevalence rate of asthmatic patients. Subsequently, it is anticipated to improve the adoption of hypodermic needles and other drug-delivery products within the projected time period.
The industry is anticipated to surge due to the rise in the predominance rate of chronic infections around the world. This increment is anticipated to boost the adoption of needles and syringes that seem to securely deliver drugs into the body system. Moreover, increasing vaccination rates were also expected to enhance the demand for novel injectable solutions, worldwide.
Various patients living with diabetes and asthma condition have been utilizing hypodermic needles on their own. These patients needed to desensitize drugs and infusions in case of distinctive unfavorably susceptible reactions. Governments around the world have been facilitating the directions and laws that permit patients to carry hypodermic needles without any major confinements. For example, in March 2021, the Maryland Senate in the United States reported the passing of a novel bill decriminalizing the dispersion and ownership of hypodermic needles.
In addition, in October 2021, the New York Government reported the passing of a bill decriminalizing the distribution and sales of hypodermic needles within the state. Beneath this novel bill, hypodermic needles would not be considered as medicate gear. The government stated that the novel bill had been introduced to enhance the accessibility of the drug delivery systems to the people.